(HROW) Harrow Health - Ratings and Ratios
Pharmaceutical,Imprinted,Drogs,Ointment,Vitamin
HROW EPS (Earnings per Share)
HROW Revenue
Description: HROW Harrow Health
Harrow Health Inc (NASDAQ:HROW) is a US-based company operating in the Pharmaceuticals sub-industry. To understand the companys financial health, lets examine the quarterly Tax Provision. A significant factor influencing this is the companys profitability and tax obligations.
Given Harrow Healths negative Return on Equity (RoE) of -17.50, it is likely that the company is currently operating at a loss. This could be due to various factors such as research and development expenses, marketing costs, or other operational expenditures. The absence of a Forward P/E ratio suggests that analysts may not have provided earnings estimates, potentially due to the companys current unprofitability.
Key economic drivers for Harrow Health include the demand for its pharmaceutical products, competition in the market, and regulatory changes affecting the industry. To gauge the companys performance, we can monitor KPIs such as revenue growth, gross margin, and operating expenses as a percentage of revenue. A potential area of focus is the companys ability to manage its cash flows and reduce operating losses.
From a trading perspective, Harrow Healths stock has shown volatility, with an Average True Range (ATR) of 2.10, representing a 5.49% price movement. The stocks beta of 0.410 indicates relatively low volatility compared to the overall market. To identify potential trading opportunities, we can analyze the stocks price movements in relation to its moving averages (SMA20, SMA50, SMA200) and other technical indicators.
To engineer a solution, we need to identify leverage points that can impact the companys financials. For instance, successful product development, strategic partnerships, or cost optimization can drive growth. By focusing on these areas and monitoring relevant KPIs, we can assess the companys progress and adjust our analysis accordingly.
HROW Stock Overview
| Market Cap in USD | 1,369m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2007-09-28 |
HROW Stock Ratings
| Growth Rating | 44.4% |
| Fundamental | 36.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -16.5% |
| Analyst Rating | 4.80 of 5 |
HROW Dividends
Currently no dividends paidHROW Growth Ratios
| Growth Correlation 3m | 86.2% |
| Growth Correlation 12m | -41% |
| Growth Correlation 5y | 85.4% |
| CAGR 5y | 74.34% |
| CAGR/Max DD 3y | 1.04 |
| CAGR/Mean DD 3y | 2.05 |
| Sharpe Ratio 12m | -0.38 |
| Alpha | 0.00 |
| Beta | 0.854 |
| Volatility | 66.92% |
| Current Volume | 601k |
| Average Volume 20d | 443.6k |
| Stop Loss | 41.1 (-4.8%) |
| Signal | 0.33 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-10.2m TTM) > 0 and > 6% of Revenue (6% = 13.7m TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA 30.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -41.29% (prev 55.69%; Δ -96.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 4.04m > Net Income -10.2m (YES >=105%, WARN >=100%) |
| Net Debt (178.3m) to EBITDA (32.1m) ratio: 5.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.9m) change vs 12m ago 9.08% (target <= -2.0% for YES) |
| Gross Margin 74.56% (prev 71.16%; Δ 3.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.87% (prev 50.27%; Δ 19.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.57 (EBITDA TTM 32.1m / Interest Expense TTM 24.9m) >= 6 (WARN >= 3) |
Altman Z'' -3.63
| (A) -0.27 = (Total Current Assets 154.9m - Total Current Liabilities 248.9m) / Total Assets 345.0m |
| (B) -0.48 = Retained Earnings (Balance) -164.2m / Total Assets 345.0m |
| (C) 0.04 = EBIT TTM 14.1m / Avg Total Assets 325.8m |
| (D) -0.56 = Book Value of Equity -164.1m / Total Liabilities 295.7m |
| Total Rating: -3.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.03
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -3.96% = -1.98 |
| 3. FCF Margin -26.74% = -7.50 |
| 4. Debt/Equity 4.49 = -2.37 |
| 5. Debt/Ebitda 6.94 = -2.50 |
| 6. ROIC - WACC (= -3.06)% = -3.82 |
| 7. RoE -17.50% = -2.50 |
| 8. Rev. Trend 94.30% = 7.07 |
| 9. EPS Trend 32.55% = 1.63 |
What is the price of HROW shares?
Over the past week, the price has changed by +11.01%, over one month by +12.60%, over three months by +41.89% and over the past year by -0.96%.
Is Harrow Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HROW is around 58.97 USD . This means that HROW is currently undervalued and has a potential upside of +36.66% (Margin of Safety).
Is HROW a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HROW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 60.1 | 39.3% |
| Analysts Target Price | 60.1 | 39.3% |
| ValueRay Target Price | 64.9 | 50.5% |
Last update: 2025-09-08 04:40
HROW Fundamental Data Overview
CCE Cash And Equivalents = 53.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 39.8406
P/S = 6.012
P/B = 27.5649
Beta = 0.333
Revenue TTM = 227.7m USD
EBIT TTM = 14.1m USD
EBITDA TTM = 32.1m USD
Long Term Debt = 38.5m USD (from longTermDebt, last quarter)
Short Term Debt = 184.4m USD (from shortTermDebt, last quarter)
Debt = 222.9m USD (Calculated: Short Term 184.4m + Long Term 38.5m)
Net Debt = 178.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.54b USD (1.37b + Debt 222.9m - CCE 53.0m)
Interest Coverage Ratio = 0.57 (Ebit TTM 14.1m / Interest Expense TTM 24.9m)
FCF Yield = -3.96% (FCF TTM -60.9m / Enterprise Value 1.54b)
FCF Margin = -26.74% (FCF TTM -60.9m / Revenue TTM 227.7m)
Net Margin = -4.49% (Net Income TTM -10.2m / Revenue TTM 227.7m)
Gross Margin = 74.56% ((Revenue TTM 227.7m - Cost of Revenue TTM 57.9m) / Revenue TTM)
Tobins Q-Ratio = -9.37 (set to none) (Enterprise Value 1.54b / Book Value Of Equity -164.1m)
Interest Expense / Debt = 2.88% (Interest Expense 6.41m / Debt 222.9m)
Taxrate = 0.0% (0.0 / 5.00m)
NOPAT = 14.1m (EBIT 14.1m * (1 - 0.00%))
Current Ratio = 0.62 (Total Current Assets 154.9m / Total Current Liabilities 248.9m)
Debt / Equity = 4.49 (Debt 222.9m / last Quarter total Stockholder Equity 49.7m)
Debt / EBITDA = 6.94 (Net Debt 178.3m / EBITDA 32.1m)
Debt / FCF = -3.66 (Debt 222.9m / FCF TTM -60.9m)
Total Stockholder Equity = 58.4m (last 4 quarters mean)
RoA = -2.96% (Net Income -10.2m, Total Assets 345.0m )
RoE = -17.50% (Net Income TTM -10.2m / Total Stockholder Equity 58.4m)
RoCE = 14.58% (Ebit 14.1m / (Equity 58.4m + L.T.Debt 38.5m))
RoIC = 5.22% (NOPAT 14.1m / Invested Capital 270.6m)
WACC = 8.28% (E(1.37b)/V(1.59b) * Re(9.16%)) + (D(222.9m)/V(1.59b) * Rd(2.88%) * (1-Tc(0.0)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.24%
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -60.9m)
EPS Correlation: 32.55 | EPS CAGR: 64.72% | SUE: 1.42 | # QB: 1
Revenue Correlation: 94.30 | Revenue CAGR: 45.28% | SUE: -0.49 | # QB: 0
Additional Sources for HROW Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle